Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease.

Nature communications·2026
Same author

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Cancer discovery·2026
Same author

Author Correction: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Nature genetics·2026
Same author

Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.

Vaccine·2025
Same author

Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Nature genetics·2025
Same author

An improved and economical LLE-LC/MS method for quantifying phosphatidylethanol: Identification and separation of isotopic cross-talk in clinical alcohol testing.

Clinical biochemistry·2025

Related Experiment Video

Updated: Jul 16, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

Molecular alterations associated with bladder cancer progression.

Marta Sánchez-Carbayo1, Carlos Cordon-Cardó

  • 1Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain. mscarbayo@cnio.es

Seminars in Oncology
|March 27, 2007
PubMed
Summary

Identifying high-risk bladder tumors requires new methods. Molecular alterations in bladder cancer progression are key to developing better diagnostics and targeted therapies for improved patient outcomes.

More Related Videos

Cell-Free DNA Integrity Analysis in Urine Samples
07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jul 16, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

Cell-Free DNA Integrity Analysis in Urine Samples
07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Area of Science:

  • Uro-oncology
  • Molecular biology
  • Cancer research

Background:

  • Superficial bladder tumors (Ta, Tis, T1) constitute 75-85% of neoplasms.
  • Over 70% of superficial bladder tumor patients experience recurrence, with a third progressing to fatal invasive disease.
  • Current treatments for invasive bladder cancer yield low cure rates (20-50%), highlighting the need for novel therapeutic targets.

Purpose of the Study:

  • To review molecular alterations in bladder cancer tumorigenesis and progression.
  • To highlight novel genes and signaling networks identified through high-throughput technologies.
  • To discuss the clinical translation of molecular targets and biomarkers for improved bladder cancer management.

Main Methods:

  • Literature review of molecular alterations in bladder cancer.
  • Analysis of high-throughput data identifying novel genes and signaling networks.
  • Discussion of the clinical utility of biomarkers for predicting progression and outcomes.

Main Results:

  • Molecular alterations are crucial in bladder cancer development and progression.
  • High-throughput technologies have identified new genetic pathways and molecular targets.
  • Integration of clinical, histological, and biomarker data can enhance predictive tools for patient management.

Conclusions:

  • New methods are essential for identifying and monitoring high-risk superficial bladder tumors.
  • Understanding molecular alterations is vital for developing targeted therapies and improving treatment selection.
  • Validated biomarkers integrated with clinical data offer a promising approach for personalized bladder cancer management.